Alterity Therapeutics Limited (ATHE) Stock Analysis & Investment Frameworks
Alterity Therapeutics Limited (ATHE) stock analysis on Invetso. Review Alterity Therapeutics Limited’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Alterity Therapeutics Limited Company Overview
- Exchange: NASDAQ Capital Market
- Sector: Healthcare
- Industry: Biotechnology
- Country: AU
Alterity Therapeutics Limited Key Financial Metrics
- Market Cap: $40.49M
- Revenue: $N/A
- ROE: -48.25%
- ROIC: -57.61%
- Dividend Yield: N/A
About Alterity Therapeutics Limited
Alterity Therapeutics Limited, an Australian biopharmaceutical firm, focuses on the discovery and development of novel drug treatments for various neurological disorders, such as Alzheimer's, Huntington's, and Parkinson's diseases. Its prominent experimental therapy, ATH434, has completed Phase I clinical trials targeting Parkinson's disease. The company is also advancing PBT2, a compound that has successfully undergone Phase IIa clinical testing for Alzheimer's disease. Established in 1997, the entity was formerly known as Prana Biotechnology Limited before rebranding to Alterity Therapeutics Limited in April 2019, and its main operations are based in Melbourne, Australia.
Alterity Therapeutics Limited Investment Frameworks
Invetso analyzes Alterity Therapeutics Limited (ATHE) across the following frameworks:
- Alterity Therapeutics Limited 10Y Growth Potential
- Alterity Therapeutics Limited Scenario Analysis
- Alterity Therapeutics Limited Risks & Opportunities
- Alterity Therapeutics Limited Economic Moat
- Alterity Therapeutics Limited Business Model
- Alterity Therapeutics Limited Management
- Alterity Therapeutics Limited SWOT Analysis
- Alterity Therapeutics Limited Porter's 5 Forces
- Alterity Therapeutics Limited PESTLE Analysis
- Alterity Therapeutics Limited ESG Analysis